Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Join us and take the first step towards a healthier you with the guidance and support of Maureen Gerry Ozempic, Mounjaro, Trulicity: Beyond the hype
1 New developments in obesity pharmacotherapy robust weight loss with the GLP- 1 receptor agonists for obesity 1.1 Weight loss efficacy There has been a transformation in medical approaches to caring for patients with obesity, sparked in 2021 by the US Food and Drug Administration approval of semaglutide 1.7 mg and 2.4 mg for chronic weight management
BPC-157 + TB-500 (Wolverine Blend) Third-Party Tested COA Available BPC-157 + TB-500 20 mg is a synthetic peptide blend used in laboratory research for peptide signaling and cellular response studies
Evidence-based strategies may include: For nausea Eating smaller meals Choosing lower-fat foods temporarily Eating slowly Avoiding long periods without food For constipation Gradually increasing fiber Drinking adequate fluids Incorporating physical activity Choosing fiber-rich foods that are well tolerated For fatigue Meeting protein needs Staying hydrated Eating consistently Monitoring for nutrient deficiencies These recommendations are individualized based on your symptoms and medical history
Rather than starting at a full therapeutic dose, many providers recommend beginning at 0.25 mg weekly and increasing over several weeks based on your appetite suppression, side effects, and weight loss rate
TIRZEPATIDE/ZEPBOUND Once-weekly injection SURMOUNT-1 Trial: Over 20% mean body weight reduction at higher doses Greater likelihood of 15% body weight reduction Newer drug with less overall evidence about effectiveness and side effects Best at improving HbA1C and blood sugar levels More rapid weight loss may also reduce lean muscle mass Possibly reduced nausea and vomiting Higher cost Requires refrigeration Weight gain common after discontinued use From $139/month LEARN MORE - GLP-1/GIP Agonists (Tirzepatide/Zepbound) SEMAGLUTIDE/WEGOVY Once-weekly injection STEP-1 Trial: Up to 15% mean body weight reduction Good long-term evidence about effectiveness and safety Evidence of reduction in diabetic and heart disease risk Slower weight loss may help maintain lean body mass and reduce gallbladder complications Nausea and vomiting similar to other medications Lower cost than Tirzepatide Requires refrigeration Weight gain common after discontinued use From $139/month LEARN MORE - GLP-1 Agonist (Semaglutide/Wegovy) WEGOVY ORAL PILL Daily oral medication Avoids injections OASIS-4 Trial: Up to 16.6% body weight reduction Similar side effect profile to injectable medications Improved blood sugar control in diabetics and pre-diabetics No refrigeration Weight gain common after discontinued use From $124/month How do I get started with a weight loss evaluation
